Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian
Edward Lee Carter, Clinical Pharmacist Practitioner at U.S. Department of Veterans Affairs, shared a post on LinkedIn:
“Factor XIa inhibition has reached clinical practice.
But the indication matters.
On November 9, 2026, the FDA approved Sunharbo (asundexian) 50 mg once daily, the first Factor XIa inhibitor authorized in the United States.
The indication is specific: secondary stroke prevention following recent mild-to-moderate noncardioembolic ischemic stroke or high-risk TIA, in combination with antiplatelet therapy.
The pivotal OCEANIC-STROKE trial randomized 12,327 patients.
Recurrent ischemic stroke:
- Asundexian: 6.2%
- Placebo: 8.4%
- HR 0.74 (95% CI 0.65–0.84)
A 26% relative reduction in the hazard of ischemic stroke.
ISTH major bleeding:
- Asundexian: 1.9%
- Placebo: 1.7%
- HR 1.10 (95% CI 0.85–1.44)
The overall difference was not statistically significant.
However, GI bleeding was more frequent, and the FDA identified bleeding concerns in older adults and early treatment.
An important electrophysiology distinction:
OCEANIC-AF previously demonstrated substantially more stroke or systemic embolism with asundexian than apixaban in patients with atrial fibrillation (HR 3.79).
That trial was terminated early.
The new approval does not change those findings.
Asundexian is not an alternative to established oral anticoagulation for AF-related stroke prevention.
For patients whose stroke mechanism remains uncertain, rhythm monitoring and reassessment for occult AF remain essential.
The stewardship challenge now shifts to implementation:
- Confirm the qualifying stroke mechanism and labeled population.
- Coordinate asundexian with appropriate single or dual antiplatelet therapy.
- Evaluate bleeding risk, particularly GI bleeding and advanced age.
- Review drug interactions, hepatic impairment, and procedural plans.
- Reassess antithrombotic therapy when AF or another cardioembolic source is identified.
The broader lesson is important:
A successful antithrombotic mechanism in one clinical setting does not establish efficacy in another.
OCEANIC-STROKE represents a meaningful advance in secondary stroke prevention.
OCEANIC-AF reminds us why indication-specific evidence and careful medication stewardship remain indispensable.
What do you see as the greatest implementation challenge: patient selection, antiplatelet coordination, or reassessment when AF is detected?”
More posts featuring Edward Lee Carter on Hemostasis Today.
-
Nov 11, 2026, 15:42Tareq Abadl: The Clinical Impact of Kell Alloimmunization
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 15:01Hassan Raza: The JAK2 V617F Revolution
-
Nov 11, 2026, 14:45ITP Is More Than a Platelet Count: Why Patient Perspectives Matter – ITP Australia and New Zealand